Skip to main content
. Author manuscript; available in PMC: 2010 Sep 1.
Published in final edited form as: J Biopharm Stat. 2009;19(3):530–542. doi: 10.1080/10543400902802458

Table 1.

Proportion of times the number of events required to provide identical power to detect a statistically significant result is greater for a treatment by marker interaction design (design 1) than for a marker-based strategy design (design 2)

Scenarios Proportion of times number of events for design 1 is greater than for design 2

Marker prevalence


Median overall survival Hazard ratios 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9
mB+ > mA+;
mA−mB−
[1.2, 1.5];
[0.9, 1.1]
0.21 0.33 0.47 0.59 0.69 0.79 0.87 0.93 0.98
mB+ > mA+;
mA− > mB−
[1.2, 1.5];
[0.67, 0.83]
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
mB+ > mA+;
mA−mB−
[1.2, 1.5];
[0.33, 0.67]
0.50 0.40 0.31 0.22 0.14 0.07 0.03 0.01 0.00
mB+mA+;
mA−mB−
[1.5, 3.0];
[0.9, 1.1]
0.35 0.61 0.77 0.87 0.93 0.97 0.99 1.00 1.00
mB+mA+;
mA− > mB−
[1.5, 3.0];
[0.67, 0.83]
0.00 0.01 0.03 0.06 0.13 0.21 0.30 0.41 0.51
mB+mA+;
mA−mB−
[1.5, 3.0];
[0.33, 0.67]
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00